Clinical Trials
31 trialsNCT05296135 2026-02-27
PREDAPT-HNSCC2
Cofactor Genomics, Inc.
Withdrawn
NCT06513884 2025-06-22
A Study of HB-202/HB-201 With Pembrolizumab in Patients With HPV16+ Recurrent/Metastatic Oropharyngeal Cancer
Hookipa Biotech GmbH
Phase 2/3 Withdrawn
NCT01345084 2025-03-28
NICAP
Eurofarma Laboratorios S.A.
Phase 3 Withdrawn
NCT05743270 2025-03-11
Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN
Replimune, Inc.
Phase 2 Withdrawn
NCT03169764 2025-02-24
QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy
ImmunityBio, Inc.
Phase 1/2 Withdrawn
NCT04985357 2024-11-25
Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
Travera Inc
Withdrawn
NCT05472506 2024-03-15
Oral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant Metastatic or Recurrent Head and Neck Cancer
Ikena Oncology
Phase 1 Withdrawn
NCT06090318 2023-10-19
Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss
Rain Oncology Inc
Phase 1/2 Withdrawn
NCT05359692 2023-09-15
INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Incyte Corporation
Phase 2 Withdrawn
NCT05220748 2023-04-19
RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients With Advanced CuSCC and HNSCC
Rakuten Medical, Inc.
Phase 1 Withdrawn
NCT03395925 2022-12-23
Evaluation of the Thyroid Volume After Radiofrequency Ablation of Thyroid Nodules and Recurrent Thyroid
Olympus Surgical Technologies Europe
Phase NA Withdrawn
NCT05393635 2022-12-20
DELTA-2
Instil Bio
Phase 1 Withdrawn
NCT04891718 2022-07-08
CIVO Intratumoural Microdosing of Anti-Cancer Therapies in Australia
Presage Biosciences
Phase EARLY_PHASE1 Withdrawn
NCT05234606 2022-04-12
A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors
Silverback Therapeutics
Phase 1/2 Withdrawn
NCT04832438 2022-02-22
9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma
Actuate Therapeutics Inc.
Phase 2 Withdrawn
NCT04129320 2022-02-08
Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck
MacroGenics
Phase 2/3 Withdrawn
NCT04408898 2021-11-16
SPEARHEAD 2 Study in Subjects With Recurrent or Metastatic Head and Neck Cancer
Adaptimmune
Phase 2 Withdrawn
NCT03939364 2021-10-19
This Study is to Evaluate the Safety and Pharmacokinetics of SBS-101 in Patients With Oral Premalignant Lesions
Skyline Biosciences
Phase 1 Withdrawn
NCT04607642 2021-10-11
Trial of BMX-001 or Placebo in Head and Neck Cancer Patients
BioMimetix JV, LLC
Phase 2 Withdrawn
NCT04464967 2021-05-12
Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers
NKGen Biotech, Inc.
Phase 1/2 Withdrawn
NCT04093115 2020-09-03
HNSCC
Beijing Konruns Pharmaceutical Co., Ltd.
Phase 2 Withdrawn
NCT03214835 2020-07-20
CDx Biopsies for Detection of Laryngopharyngeal Reflux and Laryngeal Lesions
CDx Diagnostics
Phase NA Withdrawn
NCT02624999 2020-01-22
Study Comparing AlloVaxâ„¢ to Chemotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head & Neck
Mirror Biologics, Inc.
Phase 2 Withdrawn
NCT03342352 2019-12-20
Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310)
Incyte Corporation
Phase 3 Withdrawn
NCT03386838 2019-04-18
An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck
Bristol-Myers Squibb
Phase 3 Withdrawn
NCT02143622 2016-04-21
Study of Efficacy and Safety of LJM716 and Cetuximab in Head and Neck Squamous Cell Carcinoma Patients
Novartis
Phase 1/2 Withdrawn
NCT01075841 2014-07-02
A Post-marketing Surveillance Study on Erbitux in Combination With Platinum-based Chemotherapy in Metastatic/Recurrent Squamous Cell Cancer of the Head and Neck
Merck KGaA, Darmstadt, Germany
Withdrawn
NCT01701349 2014-05-01
FACT2
Mateon Therapeutics
Phase 3 Withdrawn
NCT01506427 2012-12-17
A Study of [F-18]HX4 (PET Imaging)Evaluated in Head and Neck Cancer Patients
Siemens Molecular Imaging
Phase 1/2 Withdrawn
NCT00233636 2011-01-27
Iressa and Radiotherapy in the Treatment of the Locally Advanced Inoperable Squamous Cell Carcinoma of the Head and Neck
AstraZeneca
Phase 2 Withdrawn
NCT00540332 2009-03-02
A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Locally Advanced Head and Neck Cancer Receiving Postoperative Radiotherapy
Swedish Orphan Biovitrum
Phase 1/2 Withdrawn